Erythropoietin Stimulating Agents Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, Canada, China - Size and Forecast 2024-2028

Erythropoietin Stimulating Agents Market Size 2024-2028

The erythropoietin stimulating agents market size is forecast to increase by USD 4.51 billion, at a CAGR of 8.5% between 2023 and 2028.

• The market is experiencing significant growth due to several key factors. The presence of a large pool of Chronic Kidney Disease (CKD) patients worldwide continues to drive market demand. Furthermore, the increasing number of CKD dialysis centers in developing economies is contributing to market expansion. Strict government regulations regarding the use of ESAs in treating anemia in CKD patients ensure market stability and sustainability. These trends are expected to continue shaping the growth trajectory of the ESAs market In the coming years.

What will be the Size of the Erythropoietin Stimulating Agents Market During the Forecast Period?

Request Free Sample

• The market is driven by the increasing prevalence of surgeries, trauma cases, hypothermia, and chronic diseases, particularly In the geriatric and infant populations. ESAs play a crucial role In the treatment of various conditions, including hypoxic-ischemic encephalopathy, neurogenesis, and neuroprotection in brain injury. Mechanically ventilated patients, dialysis adoption for kidney disease and kidney failure, and hypothermia during surgical procedures are significant market growth factors. ESAs are also used in the treatment of hypothermia during surgeries, which can lead to improved patient outcomes. Intravenous warming systems and body warmers are utilized to maintain normal body temperature during surgeries, further increasing the demand for ESAs.
• The use of ESAs in critical care units, emergency department visits, and road traffic injuries is also on the rise. The increasing healthcare spending and the availability of new treatment options, such as darbepoetin, are expected to boost market growth. ESAs are also used In the treatment of motor performance issues in patients with neurological disorders and In the context of MRI scans. Overall, the market is expected to experience significant growth due to the increasing prevalence of conditions requiring ESAs and the availability of new treatment options.

How is this Erythropoietin Stimulating Agents Industry segmented and which is the largest segment?

The erythropoietin stimulating agents industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

• Type
  • Epoetin alfa
  • Epoetin beta
  • Darbepoetin alfa
  • Others
• Geography
  • North America
    • Canada
    • US
  • Europe
    • Germany
    • UK
  • Asia
    • China
  • Rest of World (ROW)

By Type Insights

• The epoetin alfa segment is estimated to witness significant growth during the forecast period.

Epoetin alfa is the dominant segment In the market due to its widespread use in treating anemia in chronic kidney disease patients and serving as an anti-coagulant to minimize the risk of blood clots during surgeries with significant blood loss. These drugs are also applicable In the treatment of HIV and cancer. Epoetin alfa functions by signaling the bone marrow to increase red blood cell production, offering a simpler mechanism compared to natural erythropoietin. Additionally, these agents find application in premature births, critical care units, road traffic injuries, and emergency department visits to manage anemia and ensure optimal oxygen supply to the body.

Get a glance at the Erythropoietin Stimulating Agents Industry report of share of various segments Request Free Sample

The epoetin alfa segment was valued at USD 3.33 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

• North America is estimated to contribute 38% to the growth of the global market during the forecast period.

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions, Request Free Sample

The market in North America experienced significant growth in 2023, with Canada, Mexico, and the US being the major contributors. This expansion is attributed to the rising number of anemia patients, expanding applications in HIV infections and end-stage renal disorders, and the risk of thrombosis during surgeries. Additionally, the market's growth is driven by the increasing prevalence of chemotherapy-induced anemia and the need for erythropoiesis in patients with pure red cell aplasia. According to recent reports, the number of cancer diagnoses in the US increased by 10% in 2021, further fueling market demand. Clinical trials continue to explore the safety and efficacy of these agents, with a focus on improving pharmacokinetics and minimizing adverse effects, such as venous thromboembolism.

Market Dynamics

Our erythropoietin stimulating agents market researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

What are the key market drivers leading to the rise In the adoption of Erythropoietin Stimulating Agents Industry?

The presence of large pool of CKD patients is the key driver of the market.

• The market is driven by the increasing prevalence of chronic kidney disease (CKD), which contributes to the development of anemia. Approximately one-third of adults with diabetes and half of those with high blood pressure are affected by CKD. Diabetes and hypertension can damage kidney blood vessels, leading to decreased EPO production and subsequent anemia. ESAs, such as Erythropoietin and Darbepoetin, stimulate the production of red blood cells (RBCs) and help maintain hemoglobin levels in patients with anemia. ESAs are essential in various clinical scenarios, including surgeries, trauma cases, hypothermia, and mechanically ventilated patients. In the geriatric and infant populations, ESAs are used to manage anemia caused by chronic diseases, such as CKD, kidney failure, and premature births.
• ESAs also play a crucial role in neuroprotection, particularly in cases of hypoxic-ischemic encephalopathy and brain injury. ESAs are administered through various methods, including intravenous warming systems, to mitigate perioperative hypothermia. They are also used in dialysis and transplantation procedures. ESAs have been shown to improve motor performance, reduce the risk of thromboembolic events, and enhance quality of life. Despite their benefits, ESAs have potential adverse effects, such as venous thromboembolism, myelosuppressive chemotherapy, and increased mortality. The risk-benefit ratio and target Hb levels are crucial considerations in patient management. Clinical trials are ongoing to evaluate the safety and efficacy of ESAs in various indications and patient populations.

What are the market trends shaping the Erythropoietin Stimulating Agents Industry?

A growing number of CKD dialysis centers in developing economies is the upcoming market trend.

• The market is experiencing significant growth due to the increasing prevalence of chronic kidney disease (CKD) and kidney failure, particularly in developing economies such as China, India, and Brazil. The rise in CKD cases is driving investments from ESA companies In these markets, as the number of dialysis centers continues to increase. For instance, NephroPlus, a leading dialysis network in Asia, recently invested USD 25 million in India to expand its operations across APAC. Similarly, Renal Project, a healthcare start-up in India, raised USD 0.3 million from angel investors to fund its expansion plans. These developments in dialysis centers are creating new opportunities for companies In the global ESA market.
• ESAs are essential in managing anemia, a common complication of CKD and kidney failure, through stimulating the production of red blood cells. ESAs are also used in various clinical applications, including surgeries, trauma cases, hypothermia, and mechanically ventilated patients. In addition, ESAs are used In the treatment of hypoxic-ischemic encephalopathy, neuroprotection in brain injury, and neurogenesis. ESAs have various applications in critical care units, including In the management of premature births, road traffic injuries, and emergency department visits. Furthermore, ESAs are used In the treatment of chronic diseases such as cancer, hematological malignancies, and solid tumors undergoing chemotherapy.
• ESAs are also used in sports endocrinology to enhance athletic performance. Despite their benefits, ESAs have potential adverse effects, including venous thromboembolism, myelosuppressive chemotherapy, chronic bleeding, malnutrition, and inflammatory cytokines. Therefore, the risk-benefit ratio and target Hb levels are crucial considerations in patient management. Treatment guidelines recommend randomized trials to determine the safety and efficacy of ESAs in various clinical applications. ESAs are administered through various routes, including intravenous and subcutaneous injections. Intravenous warming systems are used to maintain body temperature during administration to prevent perioperative hypothermia. Darbepoetin, a long-acting ESA, is commonly used due to its extended half-life, reducing the frequency of administration.

What challenges does the Erythropoietin Stimulating Agents Industry face during its growth?

Stringent government regulations is a key challenge affecting the industry growth.

• Erythropoietin stimulating agents (ESAs) are essential medications used to treat various conditions, including anemia in surgeries, trauma cases, hypothermia, geriatric population, and infant population. These agents stimulate the production of red blood cells, addressing issues related to hypoxic-ischemic encephalopathy, neurogenesis, and motor performance. ESAs are crucial in perioperative hypothermia, mechanically ventilated patients, dialysis adoption, and kidney disease, including chronic renal failure. ESAs have gained significance in treating anemia caused by chronic diseases, premature births, road traffic injuries, and emergency department visits. In critical care units, ESAs are used to manage anemia in patients with chronic bleeding, malnutrition, and inflammatory cytokines.
• Healthcare spending on ESAs has increased due to their effectiveness in improving treatment options for various conditions. Despite their benefits, ESAs face regulatory challenges due to the complex administrative systems and stringent guidelines to obtain market approval. The US Food and Drug Administration (FDA) has issued warnings regarding serious allergic reactions and thromboembolic events associated with ESAs. The risk-benefit ratio, target Hb levels, and treatment guidelines continue to evolve, with ongoing clinical trials and research focusing on pharmacokinetics, safety, and efficacy. ESAs are used in cancer treatment, including chemotherapy-induced anemia, hematological malignancies, and solid tumors. The market for ESAs is diverse, with applications in sports endocrinology, dialysis, transplantation, and neuroprotection in brain injury.

Exclusive Customer Landscape

The erythropoietin stimulating agents market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the erythropoietin stimulating agents market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

Customer Landscape

Key Companies & Market Insights

Companies are implementing various strategies, such as strategic alliances, erythropoietin stimulating agents market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence In the industry.

The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

• 3SBio Inc.
• Akebia Therapeutics
• Amgen Inc.
• Biocon Ltd.
• Biosidus SA
• Dr Reddys Laboratories Ltd.
• F. Hoffmann La Roche Ltd.
• Johnson and Johnson Services Inc.
• Nanogen Pharmaceutical Biotechnology
• NephroPlus
• Novartis AG
• Pfizer Inc.
• Reliance Industries Ltd.
• Renal Project
• Thermo Fisher Scientific Inc.
• Zydus Lifesciences Ltd.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Research Analyst Overview

Erythropoietin stimulating agents (ESAs) are a class of therapeutic agents that stimulate the production of red blood cells In the body. These agents have been utilized in various clinical settings to manage anemia and related conditions. The global market for ESAs has witnessed significant growth over the past decade due to the increasing prevalence of chronic diseases, such as kidney disease and cancer, which often result in anemia. ESAs have been shown to be effective in managing anemia in patients undergoing surgical procedures, particularly those who are at risk of perioperative hypothermia.

Hypothermia, a condition characterized by a decrease in body temperature, can lead to impaired oxygen delivery to tissues, which can result in adverse outcomes. ESAs have been used to maintain adequate hemoglobin levels in patients undergoing surgeries, ensuring optimal oxygen delivery to the body. The geriatric population and the infant population are two other groups that have benefited from ESAs. In the geriatric population, anemia is a common condition, often resulting from chronic diseases such as kidney disease or cancer. ESAs have been shown to improve quality of life and reduce the need for blood transfusions in this population.

In the case of premature infants, ESAs have been used to prevent and treat anemia of prematurity, which is a common complication in this population. ESAs have also found applications In the treatment of various chronic diseases. In patients with kidney disease, ESAs have been used to manage anemia associated with chronic renal failure. Anemia in this population can lead to fatigue, reduced exercise capacity, and impaired cognitive function. ESAs have been shown to improve hemoglobin levels and reduce the need for blood transfusions In these patients. ESAs have also been used In the treatment of anemia associated with cancer and its treatment.

Request Free Sample

What are the Key Data Covered in this Erythropoietin Stimulating Agents Market Research and Growth Report?

• CAGR of the Erythropoietin Stimulating Agents industry during the forecast period
• Detailed information on factors that will drive the Erythropoietin Stimulating Agents Market growth and forecasting between 2024 and 2028
• Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
• Accurate predictions about upcoming growth and trends and changes in consumer behaviour
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market's competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the erythropoietin stimulating agents market growth of industry companies

We can help! Our analysts can customize this erythropoietin stimulating agents market research report to meet your requirements.

Get in touch